Patrick Alexander, MD
Interventional Cardiology · Novi, MINPI 1710009006
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,118 of the $16,021 with a category attached, or 75.6%. 41 manufacturers reported payments, led by Abbott at 32.3% of the total. Reporting peaked in 2023 at $6,143 and has fallen 65.3% since, to $2,133 in 2025.
Across 237 payments — averaging $67.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Philips North America LLC$4K
- Medtronic$836
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$761
- Inari Medical, Inc.$509
- Boston Scientific$477
- plus $4K from 35 others
Across 38 payments — averaging $2373.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$51K
- Bard Peripheral Vascular, Inc.$40K
What the payments were for
- Speaking & faculty fees$2,92518%
- Travel & lodging$8725%
- Food & beverage$12,11876%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (6554) Periph Vasc Undiv$3,797
- AMPLATZER AMULET$596
- ESPRIT$535
- FLOWTRIEVER CATHETER, S$509
- CT THROMBECTOMY SYSTEM KIT$509
- ENSITE PRECISION$412
- SUPERA$261
- HawkOne$251
- Fortify Assura, Ellipse ICD$222
- (6554) Peripheral Vascular Undivided$168
- AMPLATZER Occluders$162
- Protege RX$161
- AMPLATZER$153
- Aventus$151
- GALLANT$149
- Accent Pacemaker$148
- JETi All In One Non-Sterile Kit$145
- Unify Assura CRT Defibrillator$144
- HI-TORQUE COMMAND$143
- Penumbra System$143
How this compares
$16,021 in reported general payments places this provider in the 70th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $341,565 |
| XareltoRivaroxaban | 186 | $225,422 |
| EntrestoSacubitril/Valsartan | 92 | $109,024 |
| Repatha SureclickEvolocumab | 53 | $61,002 |
| JardianceEmpagliflozin | 40 | $50,875 |
| MultaqDronedarone Hcl | 15 | $32,095 |
| FarxigaDapagliflozin Propanediol | 19 | $19,806 |
| BrilintaTicagrelor | 13 | $13,086 |
| Metoprolol Succinate | 545 | $8,983 |
| Atorvastatin Calcium | 503 | $7,035 |
| Ranolazine ErRanolazine | 55 | $5,783 |
| Carvedilol | 375 | $4,955 |
| Droxidopa | 21 | $4,723 |
| ClopidogrelClopidogrel Bisulfate | 254 | $4,574 |
| Ezetimibe | 111 | $3,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $341,565315 claims |
| Johnson & JohnsonXarelto | $160 | $225,422186 claims |
| NovartisEntresto | $211 | $109,02492 claims |
| Boehringer IngelheimJardiance | $171 | $50,87540 claims |
| AstraZenecaFarxiga, Brilinta | $52 | $32,89132 claims |
| Sanofi-aventis U.S. LLCMultaq | $29 | $32,09515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Novi
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
- Khaldoon AlaswadDetroit$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.